{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:16:13Z","timestamp":1792300573880,"version":"4.4.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The scope of this review was to review the newest developments in the context of the existing knowledge on premenopausal bone fragility. Fragility fractures are common in postmenopausal women and men and diagnostic criteria for osteoporosis have been agreed and multiple pharmacological treatments have been developed over the last 25 years. In premenopausal women, fragility fractures and very low bone mass are uncommon and osteoporosis in premenopausal women has therefore attracted much less interest.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent studies have highlighted that lifestyle and dietary habits affect premenopausal bone mass. Bone mass may be improved by sufficient intake of calcium and vitamin D together with increased physical activity in premenopausal women with idiopathic osteoporosis. If pharmacological treatment is needed, teriparatide has been demonstrated to efficiently increase bone mass; however, no fracture studies and no comparative studies against antiresorptive therapies have been conducted. Pregnancy affects bone turnover and mass significantly, but pregnancy-associated osteoporosis is a rare and heterogeneous condition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The diagnosis of osteoporosis should only be considered in premenopausal women with existing fragility fractures, diseases or treatments known to cause bone loss or fractures. Secondary causes of osteoporosis should be corrected or treated if possible. The women should be recommended sufficient intake of calcium and vitamin and physical activity. In women with recurrent fractures or secondary causes that cannot be eliminated, for example glucocorticoid or cancer treatment, pharmacological intervention with bisphosphonates or teriparatide (not in the case of cancer) may be considered.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000400","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T14:52:43Z","timestamp":1491576763000},"page":"410-415","source":"Crossref","is-referenced-by-count":57,"title":["Osteoporosis in premenopausal women"],"prefix":"10.1097","volume":"29","author":[{"given":"Bente L.","family":"Langdahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s001980200035","article-title":"Fractures before menopause: a red flag for physicians","volume":"13","author":"Hosmer","year":"2002","journal-title":"Osteoporos Int"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archinte.162.1.33","article-title":"Fractures between the ages of 20 and 50 years increase women's risk of subsequent fractures","volume":"162","author":"Wu","year":"2002","journal-title":"Arch Intern Med"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s002239900237","article-title":"Associations of early premenopausal fractures with subsequent fractures vary by sites and mechanisms of fractures","volume":"60","author":"Honkanen","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bone.2008.08.106","article-title":"International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions","volume":"43","author":"Lewiecki","year":"2008","journal-title":"Bone"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00198-012-2030-x","article-title":"Osteoporosis in young adults: pathophysiology, diagnosis, and management","volume":"23","author":"Ferrari","year":"2012","journal-title":"Osteoporos Int"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0003-9993(00)90225-9","article-title":"The relation between stress fractures and bone mineral density: evidence from active-duty Army women","volume":"81","author":"Lauder","year":"2000","journal-title":"Arch Phys Med Rehabil"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1359\/JBMR.041208","article-title":"Quantitative ultrasound: use in screening for susceptibility to stress fractures in female army recruits","volume":"20","author":"Lappe","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1302\/0301-620X.85B3.13336","article-title":"Peripheral bone mineral density in patients with distal radial fractures","volume":"85","author":"Wigderowitz","year":"2003","journal-title":"J Bone Joint Surg Br"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/01.blo.0000155345.04782.14","article-title":"Low BMD is a risk factor for low-energy Colles\u2019 fractures in women before and after menopause","volume":"435","author":"Hung","year":"2005","journal-title":"Clin Orthop Relat Res"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1210\/jcem-73-3-555","article-title":"Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence","volume":"73","author":"Bonjour","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1001\/jama.1992.03490170075028","article-title":"Bone gain in young adult women","volume":"268","author":"Recker","year":"1992","journal-title":"JAMA"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/00016470510030274","article-title":"Maternity and bone mineral density","volume":"76","author":"Karlsson","year":"2005","journal-title":"Acta Orthop"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00198-011-1654-6","article-title":"Changes in bone mineral density and body composition during pregnancy and postpartum. A controlled cohort study","volume":"23","author":"M\u00f8ller","year":"2012","journal-title":"Osteoporos Int"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00198-012-2062-2","article-title":"Changes in calcitropic hormones, bone markers and insulin-like growth factor I (IGF-I) during pregnancy and postpartum: a controlled cohort study","volume":"24","author":"M\u00f8ller","year":"2013","journal-title":"Osteoporos Int"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physrev.00027.2015","article-title":"Maternal mineral bone metabolism during pregnancy lactation and post-weaning recovery","volume":"96","author":"Kovacs","year":"2016","journal-title":"Physiol Rev"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1007\/s00198-015-3149-3","article-title":"Presentation and management of osteoporosis presenting in association with pregnancy or lactation","volume":"26","author":"Kovacs","year":"2015","journal-title":"Osteoporos Int"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00198-016-3897-8","article-title":"Pregnancy-associated osteoporosis: a case-control study","volume":"28","author":"Hadji","year":"2017","journal-title":"Osteoporos Int"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.injury.2012.03.009","article-title":"Transient osteoporosis of pregnancy","volume":"43","author":"Maliha","year":"2012","journal-title":"Injury"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s12891-016-1273-7","article-title":"Levels of serum estradiol and lifestyle factors related with bone mineral density in premenopausal Mexican women: a cross-sectional analysis","volume":"17","author":"Huitr\u00f3n-Bravo","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11657-015-0239-y","article-title":"Relationships between self-reported lifetime physical activity, estimates of current physical fitness, and a BMD in adult premenopausal women","volume":"10","author":"Greenway","year":"2015","journal-title":"Arch Osteoporos"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/8756-3282(94)90280-1","article-title":"Epidemiology and clinical features of osteoporosis in young individuals","volume":"15","author":"Khosla","year":"1994","journal-title":"Bone"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4158\/EP.6.4.296","article-title":"Osteoporosis and low bone mass in premenopausal and perimenopausal women","volume":"6","author":"Moreira Kulak","year":"2000","journal-title":"Endocr Pract"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/sarh.2002.33725","article-title":"Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women","volume":"32","author":"Peris","year":"2002","journal-title":"Semin Arthritis Rheum"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2015.03.005","article-title":"Significant bone microarchitecture impairment in premenopausal women with active celiac disease","volume":"76","author":"Zanchetta","year":"2015","journal-title":"Bone"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00223-014-9918-8","article-title":"Bone geometry, volumetric bone mineral density, microarchitecture and estimated bone strength in Caucasian females with systemic lupus erythematosus. A cross-sectional study using HR-pQCT","volume":"95","author":"Hansen","year":"2014","journal-title":"Calcif Tissue Int"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s001980070062","article-title":"Drug-induced bone loss","volume":"11","author":"Tannirandorn","year":"2000","journal-title":"Osteoporos Int"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1759720X14546350","article-title":"Medication-induced osteoporosis: screening and treatment strategies","volume":"6","author":"Panday","year":"2014","journal-title":"Ther Adv Musculoskel Dis"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12016-016-8547-6","article-title":"The impact of conventional and biological disease modifying antirheumatic drugs on bone biology, rheumatoid arthritis as a case study","volume":"51","author":"Barreira","year":"2016","journal-title":"Clinic Rev Allerg Immnunol"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.3899\/jrheum.100385","article-title":"Fractures of the proximal tibia associated with long term use of methotrexate: 3 case reports and a review of the literature","volume":"37","author":"Meier","year":"2010","journal-title":"J Rheumatol"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrrheum.2015.48","article-title":"A look behind the scenes: the risk and pathogenesis of primary osteoporosis","volume":"11","author":"Hendrickx","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1055\/s-0042-103751","article-title":"Premenopausal trabecular bone loss is associated with a family history of fragility fracture","volume":"76","author":"Prior","year":"2016","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1210\/jc.2011-1387","article-title":"Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis","volume":"96","author":"Cohen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1210\/jc.2009-0996","article-title":"Bone microarchitecture and stiffness in premenopausal women with idiopathic osteoporosis","volume":"94","author":"Cohen","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-20230828","first-page":"986","article-title":"Idiopathic osteoporosis in premenopausal women. Clinical characteristics and bone remodelling abnormalities","volume":"26","author":"Peris","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"R35-20230828","first-page":"165","article-title":"Gaucher disease: the role of the specialist on metabolic bone disease","volume":"12","author":"Masi","year":"2015","journal-title":"Clin Cases Min Bone Metab"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00223001089","article-title":"Systematic review of randomized trials of the effect of exercise on bone mass in pre and postmenopausal women","volume":"67","author":"Wallace","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1359\/JBMR.040310","article-title":"Lifestyle influences on 9-year changes in BMD in young women","volume":"19","author":"Mein","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10067-006-0405-0","article-title":"Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis","volume":"26","author":"Peris","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00774-009-0139-6","article-title":"Effects of different impact exercise modalities on bone mineral density in premenopausal women: a meta-analysis","volume":"28","author":"Martyn-St James","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2004-1659","article-title":"Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial","volume":"90","author":"Golden","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1210\/jc.2003-031885","article-title":"Effects of risedronate on bone density in anorexia nervosa","volume":"89","author":"Miller","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s00198-006-0112-3","article-title":"Bisphosphonates in pregnancy and lactation-associated osteoporosis","volume":"17","author":"O'Sullivan","year":"2006","journal-title":"Osteoporos Int"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/WHE.13.73","article-title":"A review of osteoporosis management in younger premenopausal women","volume":"10","author":"McLendon","year":"2014","journal-title":"Womens Health (Lond)"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199708073370603","article-title":"Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis","volume":"337","author":"Adachi","year":"1997","journal-title":"N Engl J Med"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","article-title":"Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status","volume":"20","author":"Langdahl","year":"2009","journal-title":"Osteoporos Int"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11914-013-0181-0","article-title":"Skeletal manifestations of treatment of breast cancer on premenopausal women","volume":"11","author":"Doo","year":"2013","journal-title":"Curr Osteoporos Rep"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","article-title":"Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?","volume":"38","author":"Hadji","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","article-title":"Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"R54-20230828","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","article-title":"Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer","volume":"27","author":"Hines","year":"2009","journal-title":"J Clin Oncol"},{"key":"R55-20230828","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00223-010-9383-y","article-title":"Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta","volume":"87","author":"Shapiro","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"},{"key":"R57-20230828","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1210\/jc.2013-1172","article-title":"Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study","volume":"98","author":"Cohen","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R58-20230828","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1210\/jc.2015-2829","article-title":"Bone density after teriparatide discontinuation in premenopausal idiopathic osteoporosis","volume":"100","author":"Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R59-20230828","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H","article-title":"Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats","volume":"60","author":"Patlas","year":"1999","journal-title":"Teratology"},{"key":"R60-20230828","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1006\/taap.1993.1148","article-title":"Effects of the bisphosphonate, alendronate, on parturition in the rat","volume":"121","author":"Minsker","year":"1993","journal-title":"Toxicol Appl Pharmacol"},{"key":"R61-20230828","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bone.2008.11.001","article-title":"Pregnancy outcome following in utero exposure to bisphosphonates","volume":"44","author":"Levy","year":"2009","journal-title":"Bone"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201707000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:38:43Z","timestamp":1693201123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201707000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000400","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}